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Abstract
Niemann-Pick A (NPA) disease is a lysosomal storage disorder (LSD) caused by a deficiency in acid sphingomyelinase (ASM)
activity. Previously, we reported that biochemical and functional abnormalities observed in ASM knockout (ASMKO) mice
could be partially alleviated by intracerebroventricular (ICV) infusion of hASM. We now show that this route of delivery also
results in widespread enzyme distribution throughout the rat brain and spinal cord. However, enzyme diffusion into CNS
parenchyma did not occur in a linear dose-dependent fashion. Moreover, although the levels of hASM detected in the rat
CNS were determined to be within the range shown to be therapeutic in ASMKO mice, the absolute amounts represented
less than 1% of the total dose administered. Finally, our results also showed that similar levels of enzyme distribution are
achieved across rodent species when the dose is normalized to CNS weight as opposed to whole body weight. Collectively,
these data suggest that the efficacy observed following ICV delivery of hASM in ASMKO mice could be scaled to CNS of the
rat.
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Introduction
Although periodic, intravenous infusions of recombinant
lysosomal enzymes has been shown to be effective at resolving
the visceral disease associated with a number of lysosomal storage
disorders (LSDs) including Gaucher, Fabry, MPS I, MPS II, MPS
VI and Pompe disease [1,2,3,4,5,6], the blood brain barrier (BBB)
has precluded this therapeutic approach from being used to treat
LSDs that display CNS neuropathology such as Niemann Pick
Type A (NPA) disease. NPA is caused by a deficiency of the
lysosomal enzyme acid sphingomyelinase (ASM) and resultant
tissue accumulation of non-degraded substrates. Patients with
NPA present with hepatosplenomegaly and a progressive neuro-
degenerative course that typically leads to death by 2 to 3 years of
age [7,8].
With respect to NPA disease, several strategies to overcome the
challenge of treating the neuropathic disease have been proposed.
These include intracerebral injection of gene, cell and protein
based therapies all of which have shown promise when tested in
the acid sphingomyelinase knockout (ASMKO) mouse model of
NPA. By delivering these therapeutics directly into the brain and
thereby bypassing the BBB, the burden of lysosomal storage of
sphingomyelin in the CNS was significantly reduced and in many
instances resulted in concomitant improvements in motor function
[9,10,11,12,13,14,15]. However, except for instances where distal
regions were targeted with viral vectors (e.g., AAV vectors) capable
axonal transport, correction of lysosomal storage pathology was
typically localized to areas that were proximal to the injection site.
Given that NPA is a global neurometabolic disease, the
development of therapeutic delivery strategies that result in
widespread correction of disease pathology throughout the CNS
is clearly desirable. One potential strategy for achieving broad
lysosomal enzyme distribution throughout the CNS is to exploit
the natural flow of cerebrospinal fluid (CSF) through either
intrathecal or intracerebroventricular (ICV) enzyme administra-
tion. Indeed, we recently reported that ICV infusion of
recombinant human acid sphingomyelinase (hASM) into ASMKO
mice led to a successful reduction in the pathological accumulation
of both sphingomyelin and cholesterol throughout the CNS [16].
In light of these encouraging results we sought to confirm that
these observations were translatable to species with a larger and
more complex nervous system. Therefore, in our current
experiments we determined the following: (1) the extent to which
regions proximal and distal to the infusion site can be targeted in
the rat CNS; (2) the relationship between the level of hASM
detected in the rat CNS and the dose infused; (3) the percentage of
the total dose detected in the rat CNS parenchyma; and (4) the
relative distribution of hASM in the rat CNS (when compared to
the mouse CNS) when the scale up dose is normalized to body
weight vs. CNS weight. Our findings indicate that ICV infusion of
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studies to extend these observations to yet larger animal models,
such as non-human primates, is warranted.
Results
ICV infusion of hASM into rats results in widespread
distribution of the enzyme throughout the CNS
Female Sprague Dawley rats (n=3/group) were infused with
either hASM (10 mg/kg) or artificial cerebrospinal fluid (aCSF)
and then killed immediately for immunohistochemical (IHC)
analysis to determine enzyme distribution within the CNS. In
enzyme-treated rats, positive hASM immunostaining was ob-
served throughout the rostral-caudal extent of the brain. Areas
that were either adjacent to the site of administration (ventricles)
or to the subarachnoid space surrounding the cortex displayed
the strongest signals (Figure 1a, S1–S6). Examination of the
regions between the ventricles and areas proximal to the
subarachnoid space at a higher magnification (46 for brain)
showed these regions also stained positively for hASM, albeit at a
lower intensity (Figure 1b). The pattern of hASM staining in the
spinal cord displayed a similar gradient of signal intensity.
Positive immunostaining was localized throughout each division
(cervical, thoracic, lumbar and sacral) of the spinal cord;
however, regions immediately adjacent to the central canal of
the spinal cord or to the subarachnoid space surrounding the
spinal cord displayed the highest intensity of staining (Figure 1a,
S6). To determine if hASM could be detected in CNS tissue in a
dose dependent manner, cohorts of rats (n=6/group) were
infused with either hASM (at a dose of 0.1, 1.0 or 10 mg/kg) or
with aCSF and were then killed immediately for ELISA analysis.
Levels of hASM in all regions of the brain (i.e., cortex, preoptic
region, striatum, hippocampus, thalamus, hypothalamus, mid-
brain, cerebellum and brainstem) of rats infused with 1 and
10 mg/kg of the enzyme were significantly higher than noted in
the control aCSF-treated animals (Figure 2a). Rats infused with
the lowest dose of hASM (0.1 mg/kg) showed higher hASM levels
(above background) only in the cortex, preoptic region, striatum
and hippocampus. While the levels of hASM in the different
regions of the brain were not significantly different from each
other, rats administered 10 mg/kg hASM showed a trend
towards higher levels in areas that were adjacent to the lateral
ventricles (e.g., striatum, hippocampus and thalamus). Interest-
ingly, although a dose response was observed, this relationship
was not linear. For example, rats treated with 10 mg/kg of hASM
only showed a 3 to 6 fold increase in hASM levels in most brain
Figure 1. (A) Distribution of hASM in the rat CNS following a 6 h ICV infusion of hASM or aCSF (S1=most rostral brain section and
S5=most caudal brain section, S6=cervical spinal cord). Positive hASM staining was observed throughout the brain and spinal cord of rats
administered with the enzyme. Staining intensity was maximal in regions proximal to ventricular compartments and the sub-arachnoid space. (B)
Higher magnification (46for brain; 206for spinal cord) of hASM staining in regions between ventricular compartments and the tissue proximal to
the sub-arachnoid space (area enclosed within the white box of sections S2 and S6). Shown are images from the brain and cervical spinal cord.
doi:10.1371/journal.pone.0016313.g001
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enzyme (Figure 2a).
All divisions of the spinal cord of rats infused with 1 and
10 mg/kg hASM showed significantly higher (p,0.01) levels of
the enzyme when compared to rats infused with aCSF
(Figure 2b). Animals administered the lowest dose of 0.1 mg/
kg hASM did not exhibit measurable amounts of enzyme above
background levels. The highest levels of hASM were detected in
the cervical region and the lowest were in the sacral division
(Figure 2b). The thoracic and lumbar regions showed interme-
diate levels. Similar to what was observed in the brain, a non-
linear dose dependent relationship was found in the spinal cord.
In fact, hASM levels detected in the spinal cord of rats infused
with 1 and 10 mg/kg were equivalent despite the 10-fold
difference in dose (Figure 2b). These data suggest that a
threshold amount of enzyme may need to be administered
before broad enzyme distribution can be attained in the CNS. In
the spinal cord, ICV infusion of 1 mg/kg may be sufficient to
maximize the delivery to this region.
Significant levels of hASM are detected in serum
following ICV infusion into rats
Given that CSF circulates back into venous circulation we also
analyzed serum for levels of hASM immediately following the
completion of the infusion procedure. In female rats hASM has a
K life of approximately 70 minutes (unpublished observations).
Significant (p,0.01) levels of hASM were detected in serum in all
hASM-infused rats regardless of the dose used (Figure 2c).
Interestingly, in contrast to what was observed in the CNS, a
linear dose-dependent relationship was observed in hASM-treated
rats. A corresponding 10-fold difference (or greater) in hASM
levels was observed between rats administered 0.1 and 1.0 mg/kg
hASM and between animals treated with 1.0 and 10 mg/kg of the
enzyme.
The absolute level of hASM detected in CNS tissue
following ICV infusion represents a small percentage of
the total infused dose
To determine how much of the total infused dose diffused
into the parenchyma of the CNS, the percent of the total hASM
delivered into different brain regions and spinal cord was
c a l c u l a t e d .I n t e r e s t i n g l y ,i nb o t ht h eb r a i na n ds p i n a lc o r do n l y
a very small fraction (less than 0.2% of the total dose) was
detected in each of the regions measured (Figures 3a, 3b).
Cumulatively, the level of hASM delivered into the brain and
spinal cord was less than 1% of the total dose administered.
Comparison of data from rats treated with 1 and 10 mg/kg
doses indicated that delivering a higher dose resulted in a
smaller percentage of the enzyme being delivered into the CNS
(Figure 3a and 3b). This observation correlates with the
findings of a non-linear dose response and suggests that at the
10 mg/kg dose, we may have saturated the processes respon-
sible for the uptake of the enzyme. However, it is unlikely that
higher levels of hASM would have been detected in CNS tissue
if the interval between the termination of the infusion
procedure and tissue collection had been increased. This
notion is based on prior observations (unpublished) which have
showed that maximal levels of hASM are detected within
visceral tissue (e.g., liver, kidney, spleen and lung) almost
immediately following systemic administration. A non-linear
dose response was also reflected by the amounts of enzyme that
were detected in the serum (Figure 3c). Interestingly, as the
dose of hASM increased 10 - fold the percentage of enzyme
detected in serum approximately doubled for subsequent dose
Figure 2. hASM levels in (A) rat brain, (B) spinal cord and (C) serum following a 6 h ICV infusion of hASM at different doses (0.1, 1.0
and 10 mg/kg) or aCSF. Significant (p,.01) levels of hASM were detected in all regions of the brain (i.e., cortex, preoptic region, striatum,
hippocampus, thalamus, hypothalamus, midbrain, cerebellum and brainstem) in rats infused with 1 and 10 mg/kg of the enzyme. Rats infused with
the 0.1 mg/kg dose displayed significant hASM levels in the cortex, preoptic region, striatum and hippocampus. No significant differences in hASM
levels between regions were observed regardless of the dose tested. In each region of the spinal cord, significant (p,.01) levels of hASM were also
detected in rats infused at either 1 or 10 mg/kg vs. rats infused with aCSF (Figureo ˆ 2b). Detected hASM levels in rats infused with 0.1 mg/kg were not
significantly above background. Significant (p,.01) levels of hASM were detected in serum for all hASM infused rats regardless of the dose of enzyme
used.
doi:10.1371/journal.pone.0016313.g002
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Figure 3c).
Similar levels of hASM are detected in the CNS of rats and
mice when the dose is normalized to CNS weight rather
than body weight
Previously, we reported that ICV infusion of 1 mg/kg hASM
was the lowest effective dose to reduce lysosomal accumulation of
sphingomylein (the primary substrate of hASM) in a mouse model
of Niemann Pick A disease [16]. In the current study, we measured
hASM levels attained within specific regions of the mouse CNS
following infusion at this same dose to determine the tissue levels
needed for the observed efficacy (n=8). It is currently unclear,
however, if species scale up doses should be normalized to body
weight (BW) which is 10–15 fold greater in rats (assuming rat
BW=0.3 kg) or CNS weight (CW) which is approximately 5 fold
greater in rats (assuming rat CW=0.028 kg). Therefore, to
determine which dose scaling metric should be employed for
ICV enzyme infusion, the results of the current mouse experiment
were compared with the findings observed in rats infused with
1 mg enzyme/kg of BW (i.e., 0.3 mg total dose) and rats (n=6)
that were administered a dose of 46 enzyme mg/kg of CW (i.e.,
0.128 mg total dose). In ASMKO mice 46 mg/kg of CW is the
lowest effective dose when the dose is normalized to CW. ICV
infusion of hASM into mice (at 1 mg/kg of BW or 46 mg/kg when
normalized to CW) resulted in significant (p,.01) enzyme
distribution throughout all brain regions examined (i.e., cortex,
striatum, hippocampus, thalamus, hypothalamus, midbrain, cer-
ebellum and brainstem; Figure 4a). In contrast to the brain, the
levels of hASM in the mouse spinal cord were not significantly
above background (noted in matched tissues from aCSF-infused
mice) in the majority of animals analyzed (Figure 4b). Rats infused
with an equivalent dose based on BW (1.0 mg/kg) displayed levels
of hASM that were significantly (p,0.01) higher in both the brain
and spinal cord than what was noted in mice treated with hASM
(Figure 4a, 4b). Interestingly, when rats were administered an
equivalent dose based on CW (46 mg/kg) the levels of hASM
attained in the majority of CNS regions analyzed were fairly
comparable between species (Figure 4a, 4b). The only notable
differences were in the thalamus and in the spinal cord. Similar to
the observations in the CNS, serum hASM levels were also
significantly (p,.01) higher in rats than in mice when the dose
administered had been normalized based on their BW. Rats that
were infused at a dose that had been normalized based on their
CW displayed serum hASM levels that were not significantly
different from the levels detected in mice (Figure 4c).
Discussion
The blood brain barrier (BBB) has proven to be a formidable
obstacle in the development of therapeutic treatments for several
neurodegenerative disease including neuropathic lysosomal stor-
age diseases (LSDs) such as Niemann Pick Type A (NPA) disease.
Circumventing the BBB through intracerebroventricular (ICV)
drug administration has been reported to be a viable approach for
addressing several CNS disease states including brain infection,
brain tumors, and intracerebral hemorrhage [17,18,19,20,21].
Indeed, recently we had reported that ICV infusion of recombi-
nant human acid sphingomyelinase (hASM) in a mouse model of
NPA disease (i.e., ASMKO mice) led to widespread enzyme
delivery throughout the CNS in a manner that significantly
reduced pathological lysosomal substrate accumulation in the
brain and spinal cord [16]. Therefore, in our current experiments
we further explored the translatability of this therapeutic delivery
approach by comparing the distribution of hASM in the rat and
mouse CNS following ICV infusion.
Translation of therapeutic observations made in mouse models
of CNS disease to a non-human species with a larger and more
complex nervous system is in most instances a prerequisite to
testing an experimental therapy in man. Testing CNS drugs in rats
has proven to be a useful intermediate step to assess a therapeutic
agent’s permeation and distribution within the CNS prior to
Figure 3. Percentage of the total administered dose of hASM detected in the (A) brain, (B) spinal cord and (C) serum of rats
following 6 h ICV infusion. Animals were infused with 0.1, 1.0 or 10 mg/kg of hASM or aCSF. For both the brain and spinal cord, less than 0.2% of
the total dose could be detected in each region. Cumulatively, the level of hASM detected in the brain and spinal cord was less than 1% of the total
dose administered. No significant differences were observed between regions or different dose groups. Significant (p,.01) levels of hASM were
detected in serum for each dose.
doi:10.1371/journal.pone.0016313.g003
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human primates. Brain pharmacokinetic studies performed in rats
have the potential to be especially useful when such experiments
are linked to neurochemical, physiological, behavioural or
neuroimaging readouts that support target activation; however,
the first step is to demonstrate adequate distribution of the
therapeutic agent (i.e., at a concentration shown to be efficacious
in mouse models of the disease) within target regions of the CNS.
In the case of neuropathic LSDs such as NPA, the target region is
the entire CNS as NPA is a global neurometabolic disease.
Immunohistochemical (IHC) examination of the rat CNS
following ICV infusion (at a concentration of 10 mg/kg) showed
the enzyme was widely distributed throughout the rostral-caudal
extent of both the brain and spinal cord. Interestingly, the intensity
of hASM staining was strongest in regions that were proximal to
the ventricle and the sub-arachnoid space surrounding the brain.
This pattern of staining was not readily apparent in all CNS
regions analyzed in our prior ASMKO mouse studies [16]. In
agreement with the IHC findings, ELISA measurements revealed
significant levels of hASM throughout discrete regions of the brain
(i.e., cortex, preoptic region, striatum, hippocampus, thalamus,
hypothalamus, midbrain, cerebellum and brainstem) and each
division of the spinal cord. Although there were no significant
regional variations at the whole tissue level, there was a trend for
detecting higher levels of hASM in regions that were proximal to
the lateral ventricles (e.g., hippocampus). Similar findings were
made in the spinal cord, as a gradient of hASM was observed with
the highest levels being in the cervical and the lowest in sacral
divisions.
The effect of administering increasing doses of hASM on its
distribution in the CNS was also examined. Although ICV
infusion of hASM at lower doses (i.e., 0.1 and 1.0 mg/kg) resulted
in measureable amounts of hASM within the CNS (depending on
the dose and brain region analyzed), the level of hASM detected
was not directly proportional to the dose infused. For example,
when hASM levels were compared in rats dosed at 10 mg/kg vs.
1 mg/kg only a 3–6 fold increase in detected hASM levels was
found in most brain regions analyzed despite the fact a 10-fold
higher dose was employed. Interestingly, rats treated with 1.0 and
10 mg/kg hASM displayed equivalent levels of hASM through-
out the spinal cord. These results suggest that the amount of
hASM that diffuses into CNS parenchyma (especially to the
spinal cord) or that undergoes cellular uptake following ICV
infusion is limited and is not linearly dependent upon the
concentration of the enzyme delivered to the CSF compartment.
Several additional findings from our current studies support this
view. Specifically, we found that less than 1.0% of the total dose
delivered to the lateral ventricle was detected in CNS tissue
regardless of the dose infused. In addition, a higher percentage of
the total dose administered was detected in CNS tissues of rats
treated with lower vs. higher doses (e.g., 1.0 vs. 10 mg/kg).
Moreover, a significant dose-dependent increase in serum hASM
levels was observed following ICV infusion. The latter finding
was expected given that CSF flows out of the ventricular system
into the subarachnoid space and into the venous circulation in
part through the arachnoid villi in the venous sinuses [22,23]
Although we found significant levels of hASM in serum following
ICV infusion, a significant percentage of the total dose still
remained unaccounted for. It is likely that a significant
percentage of the infused enzyme was internalized by the visceral
tissues and/or delivered to the lymphatic system. This supposition
is supported by our earlier work demonstrating that ICV infusion
of hASM into ASMKO mice led to a significant reduction in
lysosomal accumulation of sphingomyelin in several visceral
organs including the spleen, liver and lungs [16]. Although we
have not assessed this directly, it is expected that a significant
amount of hASM would also be found in the lymphatic system as
it serves as a major drainage route for CSF leaving the CNS
[22,23,24].
A number of cellular and diffusion barriers (e.g., size and
charge of hASM, enzymatic inactivation, and sequestration of
the enzyme by binding proteins) may have been responsible for
limiting the penetration and diffusion of hASM into surrounding
CNS parenchyma following ICV infusion. Although neighboring
ependyma cells are linked by gap rather than tight junctions to
facilitate the outflow of endogenous polypeptides (e.g., leptin and
Figure 4. Comparison of hASM levels in the (A) brain, (B) spinal cord and (C) serum of rats and mice infused at equivalent doses
normalized to body weight (BW) and CNS weight (CW). Mouse BW dose of 1 mg/kg is approximately equal to 46 mg/kg/CW when converted.
ICV hASM infusion in mice (at 1 mg/kg/BW or 46 mg/kg/CW) resulted in significant (p,.01) enzyme distribution throughout all of the brain regions
examined (i.e., cortex, striatum, hippocampus, thalamus, hypothalamus, midbrain, cerebellum and brainstem) vs. aCSF infused mice. hASM levels in
the mouse spinal cord were not significantly above background. Rats infused at equivalent dose based on BW (1.0 mg/kg) displayed levels of hASM
that were significantly (p,.01) several fold higher for both the brain and spinal cord. hASM levels in rats infused at an equivalent CW dose (46 mg/kg)
were comparable to levels detected in the mouse CNS. Serum hASM levels were significantly (p,.01) several fold higher in rats vs. mice infused at
comparable BW dose, whereas rats infused at an equivalent CW dose displayed serum hASM levels that were not significantly different from levels
detected in mice.
doi:10.1371/journal.pone.0016313.g004
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relatively large size of hASM (72 kDa) may have restricted its
penetration into CNS tissue. For example, it has been reported
that smaller, hydrophilic peptides (e.g., leptin, 16 kDa) can be
widely distributed throughout the CNS upon ICV delivery
whereas larger polypeptides (e.g., FGF-2, 22 kDa; GDNF,
24 kDa) which also have an affinity for components (e.g.,
heparan sulfate) of the extracellular matrix have a more limited
distribution [26,27]. Alternatively, detection of low levels of
hASM in CNS parenchyma may be due to accelerated removal
of hASM through efflux pumps (e.g., p-glycogprotein multidrug-
resistance pump); as it has been suggested that ependymal cells
possess both the structural and enzymatic machinery that is
necessary for scavenging a wide variety of substances in the CSF
to form a metabolic barrier at the brain-CSF interface [25].
Enzymatic inactivation of the infused hASM by the choroid
plexus (CP) may have also been responsible given that the CP
expresses a number of different peptidases [26]. Finally, it is also
possible that enzyme diffusion may not be limiting and that only
a small percentage of the total dose is detected in CNS tissue
because the cellular uptake of hASM, which is mannose 6-
phosphate receptor (M6PR)-mediated [28,29], becomes saturat-
ed after a given enzyme concentration is achieved (i.e., when
maximal M6PR occupation occurs or after enzyme internaliza-
tion becomes saturated). Clearly additional experiments are
necessary to determine M6PR distribution within CNS tissue,
which cell types express M6PR receptors, the dose at which
M6PRs reach saturation and the K life of hASM in CNS
parenchyma in order to better understand the potential of ICV
enzyme infusion as a therapeutic delivery approach for the
treatment of neuropathic LSDs. However, we believe that these
questions will best be answered in an animal model (e.g., non
human primate) with a CNS composition that is more similar to
human.
Nevertheless, despite the fact that only a small percentage of
the total ICV administered dose was detected in rat CNS
parenchyma, hASM was distributed throughout the CNS and at
a level (2–10 ng/region) that is predicted to be within the
therapeutic range necessary to be efficacious in the ASMKO
mouse CNS [16]. We also demonstrated for the first time that
equivalent levels of enzyme are detected in CNS parenchyma and
serum when the administered dose was normalized to CNS
weight rather than body weight. Prior to our current experiments
guidance from the literature indicating which metric should be
used for calculating a species scale up dose for ICV enzyme
infusion was lacking. This information may prove to be
particularly useful in designing experiments that test ICV enzyme
infusion in yet larger animal models. This finding is also
important from a safety perspective because the physical chemical
properties (i.e., osmolarity, pH and the presence of preservatives
and diluents) of potential therapeutics can present serious
challenges (e.g., initiate seizures, hyperaesthesia and contribute
to tachyphlaxis) to whether or not a potential drug therapy can be
safely and effectively administered through the ICV delivery
route [18].
In conclusion, our results indicate that ICV infusion leads to
widespread hASM delivery throughout the CNS in rats at a level
shown to be efficacious in ASMKO mice. More experimentation
is needed to understand the factors limiting the delivery of the
enzyme to the CNS parenchyma following ICV infusion and
whether the diffusion/cellular uptake barriers will preclude
delivery of clinically relevant levels of hASM to a species with a
brain mass and complexity that is more similar to humans (e.g.
non- human primate).
Methods
Animals
Thirty-six female Sprague Dawley rats (8 to 10 weeks old) and
sixteen female C57BL/6 mice (8 to 10 weeks old) were obtained
from Charles River Laboratories (Wilmington, MA), maintained
under a 12 hr/12 hr light/dark cycle and given water and food ad
libitum throughout the study period. All procedures were
performed using a protocol (08-1218-03) that had been approved
by the Institutional Animal Care and Use Committee at Genzyme.
Stereotaxic surgery
Mice and rats were anesthetized with 3% isofluorane and
placed in a stereotaxic frame for placement of an indwelling guide
cannula (Plastics One, Roanoke, VA) to a position that was 1 mm
dorsal to the right lateral ventricle (mouse coordinates: A–P: 2.4
from bregma, M–L: 21.0 from bregma, D–V: 21.05 from dura,
incisor bar: 0.0; rat coordinates: A–P: 21.25 from bregma, M–L:
21.4 from bregma, D–V: 23.2 from dura, incisor bar: 0.0). Guide
cannulas were permanently affixed to the skull using anchor screws
(CMA Microdialysis Inc., North Chelmsford, MA) and dental
acrylic (CMA Microdialysis Inc., North Chelmsford, MA). A
dummy cannula (Plastics One, Roanoke, VA) was inserted into the
guide cannula to maintain cannula patency prior to insertion of
the infusion probe. One hour before and 24 h after surgery,
rodents were given ketoprofen (5 mg/kg, administered subcuta-
neously) for analgesia.
Intracerebroventricular infusion
On the day of enzyme infusion, the dummy cannula was
removed and replaced with an infusion probe (Plastics One,
Roanoke, VA) that extended 1 mm ventral to the tip of the guide
cannula. Infusion probes were connected to a swivel (Instech
Laboratories Inc., Plymouth Meeting, PA) using a tubing that
permitted 360 degrees of movement during the infusion
procedure. Swivels were connected with tubing to a Hamilton
gastight syringe mounted on a Harvard Apparatus infusion pump
(Harvard Apparatus, Holliston, Massachusetts) set to deliver
enzyme (at variable concentrations depending on the experiment)
at a rate approximately equivalent to a quarter of the normal rate
of turnover of endogenous CSF (mice: 5 ul/h; rats: 20 ul/h) for up
to 6 h. Upon completion of the infusion procedure, infusion
probes were then removed and replaced with the dummy
cannulas.
Tissue collection and processing
Animals were killed immediately following the infusion
procedure according to a humane protocol approved by the
Institutional Animal Care and Use Committee. Following an
anesthetic over dose with euthasol, rodents underwent a terminal
retro-orbital eye bleed to collect serum for subsequent ELISA of
hASM. Animals destined for biochemical analysis were perfused
through the heart with phosphate-buffered saline (PBS) to remove
all blood. Brain and spinal cord tissue were harvested and snap
frozen in liquid nitrogen as reported previously [9,11]. Prior to
being snap frozen, brain tissue was dissected into the following
regions: cortex, striatum, preoptic region, hippocampus, hypo-
thalamus, thalamus, midbrain, cerebellum and brainstem. Simi-
larly, the spinal cord was dissected into cervical, thoracic, lumbar
and sacral segments prior to being snap frozen. Animals destined
for histological analyses were perfused with 4% paraformaldehyde,
and the tissues sectioned on a vibratome as reported previously
[12].
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Brain sections were stained for hASM using a biotinylated anti-
hASM monoclonal antibody (Genzyme, Framingham, MA) at a
dilution of 1:200 and visualized as reported [12]. An ELISA
specific for hASM (Genzyme, Framingham, MA) was used to
quantify the level of the enzyme in serum samples as reported [9].
Statistics
Levels of hASM in the tissues and serum were analyzed with
ANOVAs. Follow-up analyses were conducted with a Bonferroni
post-hoc test where appropriate. All values were considered
significant if p,0.05.
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